var data={"title":"Amphotericin B deoxycholate (conventional): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amphotericin B deoxycholate (conventional): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5633?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amphotericin B deoxycholate (conventional): Patient drug information&quot;</a> and <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amphotericin B deoxycholate (conventional): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7254335\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">This drug should be used primarily for treatment of patients with progressive and potentially life-threatening fungal infections; it should not be used to treat noninvasive forms of fungal disease such as oral thrush, vaginal candidiasis, and esophageal candidiasis in patients with normal neutrophil counts.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Error prevention:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Exercise caution to prevent inadvertent overdose with amphotericin B. Verify the product name and dosage if dose exceeds 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134687\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fungizone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134709\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134690\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Conventional amphotericin formulations (desoxycholate [Amphocin, Fungizone]) may be confused with lipid-based formulations (AmBisome, Abelcet, Amphotec). Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosage recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: Premedication:</b> For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: NSAID and/or diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Test dose:</b> IV: 1 mg infused over 20 to 30 minutes. Many clinicians believe a test dose is unnecessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible fungal infections:</b> IV: Adults: 0.3 to 1.5 mg/kg/day; 1 to 1.5 mg/kg over 4 to 6 hours every other day may be given once therapy is established; aspergillosis, rhinocerebral mucormycosis, often require 1 to 1.5 mg/kg/day; do not exceed 1.5 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillosis, disseminated:</b> IV: 0.6 to 0.7 mg/kg/day for 3 to 6 months. <b>Note:</b> IDSA recommends amphotericin B (conventional) be reserved for use in resource limited settings when no alternatives are available; voriconazole is preferred therapy for invasive <i>Aspergillus</i> infections (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillosis (ocular) (off-label use):</b> Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intraocular: Inject 5 to 10 mcg in a 0.1 mL volume as a single dose intravitreally or intracamerally to the affected eye; may be repeated in 4 to 7 days as clinically indicated (Kaushik 2001; Patterson 2016). Guidelines recommend concomitant vitrectomy and use in combination with systemic voriconazole (Patterson 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Topical (0.1% to 0.2% solution): Apply to affected eye every 30 to 60 minutes until symptoms resolve (may take weeks) (Kaushik 2001; Ritterband 2002; Tamcelik 2002). <b>Note:</b> Ophthalmic natamycin is the preferred treatment (Patterson 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blastomycosis:</b> Moderately severe to severe pulmonary disease, disseminated extrapulmonary disease or immunosuppressed patients: IV: 0.7 to 1 mg/kg/day for 1 to 2 weeks or until improvement is noted, followed by oral itraconazole for 6 to 12 months (IDSA [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CNS infection (when ventricular device cannot be removed) (off-label)<i>: </i>Intraventricular: 0.01 to 0.5 mg/2 mL of an extemporaneously prepared solution in D5W administered through the device into the ventricle (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endophthalmitis due to <i>Candida</i> (off-label use): Patients with vitritis or with macular involvement (with or without vitritis): Intravitreal: 5 to 10 mcg/0.1 mL of an extemporaneously prepared solution in sterile water; administer with concomitant systemic antifungal therapy (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Esophageal:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Non-HIV-infected patients (alternative therapy) (off-label use): </i>IV: 0.3 to 0.7 mg/kg/day. Consider step down to an oral antifungal once patient is able to tolerate oral intake. In fluconazole-refractory disease, continue amphotericin B (conventional) for 21 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HIV-infected patients (alternative therapy) (off-label use):</i> IV: 0.6 mg/kg/day for 14 to 21 days (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oropharyngeal (fluconazole-refractory): <i>Non-HIV-infected patients (alternative therapy) (off-label use):</i> Oral: 100 mg of an extemporaneously compounded 100 mg/mL suspension 4 times daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Urinary tract candidiasis (off-label use) (IDSA [Pappas 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Asymptomatic candiduria in patients undergoing urologic procedures:</i> IV: 0.3 to 0.6 mg/kg daily for several days before and after the procedure</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Fungus balls:</i> Irrigation via nephrostomy tubes (off-label route): Irrigate with an extemporaneously prepared solution of 25 to 50 mg in 200 to 500 mL sterile water (final concentration range: 0.05 to 0.25 mg/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pyelonephritis:</i> <i>C. krusei or fluconazole-resistant C. glabrata: </i>IV: 0.3 to 0.6 mg/kg/day for 1 to 7 days (with or without flucytosine for fluconazole-resistant <i>C. glabrata</i>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Symptomatic cystitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>C. krusei or fluconazole-resistant C. glabrata: </i>IV: 0.3 to 0.6 mg/kg/day for 1 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Fluconazole-resistant species (eg. C. krusei, C. glabrata) </i>Bladder irrigation (off-label route): Irrigate with a 0.05 mg/mL (50 mg/L) sterile water solution instilled for 5 to 7 days or until cultures are clear. <b>Note:</b> Recommended for use in conjunction with other treatment modalities (Fisher 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis in HIV-infected patients with severe, non-meningeal infection (ie, diffuse pulmonary or severely ill with extrathoracic disseminated disease):</b> IV: 0.7 to 1 mg/kg/day until clinical improvement, then initiate triazole therapy (eg, fluconazole or itraconazole) (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcal disease, HIV-infected patients:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Disseminated (non-CNS disease) or severe pulmonary disease: Induction: 0.7 to 1 mg/kg/day (with flucytosine [preferred] or fluconazole or without a concomitant agent) for 2 weeks, then change to oral fluconazole for consolidation/maintenance therapy (HHS [OI adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis: IV: Induction: 0.7 to 1 mg/kg/day (with flucytosine [preferred] or fluconazole or without a concomitant agent) for 2 weeks, then change to oral fluconazole for consolidation/maintenance therapy (HHS [OI adult] 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis:</b> <i>Moderately severe to severe pulmonary or disseminated disease (off-label)</i>: IV: 0.7 to 1 mg/kg/day for 1 to 2 weeks, followed by oral itraconazole for 12 weeks (pulmonary disease) or 12 months (disseminated disease) (IDSA [Wheat 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis, visceral, HIV-infected (alternative agent) (off-label<b>)</b>: </b>IV: 0.5 to 1 mg/kg/dose once daily for a total cumulative dose of 1,500 to 2,000 mg (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sporotrichosis:</b> Pulmonary, meningeal, osteoarticular, or disseminated (off-label): IV: 0.7 to 1 mg/kg/day; after the patient has shown a favorable response, can change to oral itraconazole for suppressive therapy for a total duration of therapy of &ge;12 months (IDSA [Kauffman 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134703\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amphotericin B deoxycholate (conventional): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Conventional amphotericin formulations (desoxycholate [Amphocil, Fungizone]) may be confused with lipid-based formulations (AmBisome, Abelcet, Amphotec). Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosage recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: Premedication:</b> For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: NSAID and/or diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Test dose:</b> IV: Infants and Children: 0.1 mg/kg/dose to a maximum of 1 mg; infuse over 30 to 60 minutes. Many clinicians believe a test dose is unnecessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Susceptible fungal infections</b>: IV: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 0.25 to 0.5 mg/kg/dose once daily; gradually increase daily, usually in 0.25 mg/kg increments until the desired daily dose is reached (maximum daily dose: 1.5 mg/kg/<b>day</b>); in critically ill patients, more rapid dosage acceleration may be warranted (eg, &ge;0.5 mg/kg daily dose increase); others have initiated at target dose for life-threatening infection (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance dose: 0.25 to 1 mg/kg/dose once daily; rapidly progressing disease may require short-term use of doses up to 1.5 mg/kg/<b>day</b>; once therapy has been established, amphotericin B may be administered on an every-other-day basis at 1 to 1.5 mg/kg/dose in some cases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Duration of therapy varies with nature of infection: Usual duration is 4 to 12 weeks or cumulative dose of 1 to 4 g.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Indication-specific dosing: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis endocarditis (off-label):</b> Children and Adolescents: IV: 1 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocarditis (off-label): Children and Adolescents: IV: 1 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Invasive (off-label): Infants, Children, and Adolescents: IV: 0.5 to 1 mg/kg/dose once daily; duration of therapy dependent upon severity and site of infection (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Esophageal (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-exposed/-positive: </i>Infants, Children, and Adolescents: IV: 0.3 to 0.7 mg/kg/dose once daily; consider step down to an oral antifungal once patient is able to tolerate oral intake. In fluconazole-refractory disease, continue amphotericin B for 21 days (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 0.3 to 0.7 mg/kg/dose once daily (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Urinary tract infections (off-label use; IDSA [Pappas 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis, urologic procedures in patients with candiduria: Infants, Children, and Adolescents: IV: 0.3 to 0.6 mg/kg/dose once daily for several days before and after procedure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cystitis: Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Asymptomatic (high-risk patients): 1 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Symptomatic<i> (C. krusei or fluconazole-resistant C. glabrata)</i>: 0.3 to 0.6 mg/kg/dose once daily for 1 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pyelonephritis: Infants, Children, and Adolescents: IV: 0.3 to 0.6 mg/kg/dose once daily for 1 to 7 days; depending on organism, consider addition of flucytosine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Coccidioidomycosis (HIV-exposed/-positive) (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Disseminated (non-CNS) disease, diffuse pulmonary disease; severely ill:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: IV: 0.5 to 1 mg/kg/dose once daily until clinical improvement; minimum of several weeks of therapy (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryptococcal disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS disease (off-label):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-exposed/-positive:</i> Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily plus flucytosine; <b>Note:</b> Minimum 2- to 4-week induction, followed by consolidation and chronic suppressive therapy; may increase amphotericin dose to 1.5 mg/kg/<b>day</b> if flucytosine is not tolerated (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 1 mg/kg/dose once daily plus flucytosine or fluconazole; <b>Note:</b> Minimum 2-week induction, followed by consolidation and chronic suppressive therapy; a longer duration of induction therapy may be necessary if CSF is not negative or lack of clinical improvement; may increase amphotericin dose to 1.5 mg/kg/<b>day</b> alone or in combination with fluconazole if flucytosine is not tolerated (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Disseminated (non-CNS disease) or severe pulmonary disease (off-label):<i> Independent of HIV status:</i> Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily with or without flucytosine; duration of therapy depends on the site and severity of the infection and clinical response (HHS [OI adult 2017]; HHS [OI pediatric 2013]; IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Histoplasmosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Non-HIV-exposed/-positive:</i> Severe disseminated (non-CNS) or pulmonary disease (off-label): Infants, Children, and Adolescents: IV: 0.7 to 1 mg/kg/dose once daily; <b>Note:</b> Minimum 1- to 2-week induction, followed by consolidation therapy (IDSA [Wheat 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-exposed/-positive:</i> CNS or severe disseminated disease (off-label): Infants and Children: IV: 0.7 to 1 mg/kg/dose once daily, followed by consolidation therapy (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Duration of induction:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe or moderately severe pulmonary disease: 1 to 2 week minimum</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Disseminated or clinical improvement delayed: &ge;2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CNS involvement: 4 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leishmaniasis, visceral (HIV-exposed/-positive) (off-label<b>)</b>: </b>Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134691\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134692\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If renal dysfunction is due to the drug, the daily total can be decreased by 50% or the dose can be given every other day. IV therapy may take several months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal replacement therapy: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis or CRRT.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22902758\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134665\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as desoxycholate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134650\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F747024\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: May be infused over 4 to 6 hours. For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal (eg, ibuprofen, choline magnesium trisalicylate) &plusmn; diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered. Bolus infusion of normal saline immediately preceding, or immediately preceding and following amphotericin B may reduce drug-induced nephrotoxicity. Risk of nephrotoxicity increases with amphotericin B doses &gt;1 mg/kg/day. Infusion of admixtures more concentrated than 0.25 mg/mL should be limited to patients absolutely requiring volume contraction. Pre-infusion administration of 500 to 1,000 mL of normal saline appears to reduce the risk of nephrotoxicity during amphotericin B treatment (HHS [OI adult 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irrigation (off-label route): A solution for irrigation (final concentration range: 0.05 to 0.25 mg/mL) may be administered via nephrostomy tubes for fungal balls associated with UTI due to candida. A solution for irrigation (final concentration: 0.05 mg/mL solution) may be instilled via bladder irrigation for cystitis (IDSA [Pappas 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134669\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Life-threatening fungal infections:</b> Treatment of patients with progressive, potentially life-threatening fungal infections: Aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, zygomycosis (including mucormycosis due to susceptible species of the genera <i>Absidia, Mucor,</i> and <i>Rhizopus</i>), and infections due to related susceptible species of <i>Conidiobolus,</i> <i>Basidiobolus,</i> and sporotrichosis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leishmaniasis:</b> May be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475062\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Candidiasis, endophthalmitis (intravitreal); Candidiasis, esophageal (non-HIV-infected patients); Candidiasis, esophageal, in HIV-infected patients (adolescents and adults); Candidiasis, esophageal, in HIV-exposed/-infected patients (infants/children); Candidiasis, oropharyngeal (fluconazole-refractory) (oral); Candidiasis, urinary tract; Ocular aspergillosis (ophthalmic)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134718\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Conventional amphotericin formulations (Amphocin, Fungizone) may be confused with lipid-based formulations (AmBisome, Abelcet, Amphotec).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134657\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills, headache (less frequent with I.T.), malaise, pain (less frequent with I.T.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia, hypomagnesemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia, diarrhea, epigastric pain, heartburn, nausea (less frequent with I.T.), stomach cramps, vomiting (less frequent with I.T.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (normochromic-normocytic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (with or without phlebitis or thrombophlebitis [incidence may increase with peripheral infusion of admixtures])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal function abnormality (including azotemia, renal tubular acidosis, nephrocalcinosis [&gt;0.1 mg/ml]), renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing, hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Arachnoiditis, delirium, neuralgia (lumbar; especially with intrathecal therapy), paresthesia (especially with intrathecal therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukocytosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% (Limited to important or life-threatening): Acute hepatic failure, agranulocytosis, anuria, blood coagulation disorder, bone marrow depression, bronchospasm, cardiac arrest, cardiac arrhythmia, cardiac failure, convulsions, diplopia, dyspnea, eosinophilia, exfoliation of skin, hearing loss, hemorrhagic gastroenteritis, hepatitis, hypersensitivity pneumonitis, increased liver enzymes, jaundice, leukoencephalopathy, leukopenia, maculopapular rash, melena, nephrogenic diabetes insipidus, oliguria, peripheral neuropathy, pruritus, pulmonary edema, renal failure, renal tubular acidosis, shock, Stevens-Johnson syndrome, thrombocytopenia, tinnitus, toxic epidermal necrolysis, ventricular fibrillation, vertigo (transient), visual disturbance, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134672\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amphotericin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134654\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; during the initial dosing, the drug should be administered under close clinical observation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Acute reactions (eg, fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, tachypnea) may occur 1 to 3 hours after starting an intravenous infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Avoid rapid infusion to prevent hypotension, hypokalemia, arrhythmias, and shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukoencephalopathy: Has been reported following administration of amphotericin. Total body irradiation has been reported to be a possible predisposition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: May cause nephrotoxicity; usual risk factors include underlying renal disease, concomitant nephrotoxic medications and daily and/or cumulative dosing of amphotericin. Avoid use with other nephrotoxic drugs; drug-induced renal toxicity usually improves with interrupting therapy, decreasing dosage, or increasing dosing interval. However permanent impairment may occur, especially in patients receiving large cumulative dose (eg, &gt;5 g) and in those also receiving other nephrotoxic drugs. Hydration and sodium repletion prior to administration may reduce the risk of developing nephrotoxicity. Frequent monitoring of renal function is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fungal infections: <b>[US Boxed Warning]: Should be used primarily for treatment of progressive, potentially life-threatening fungal infections, not noninvasive forms of infection.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenic patients: Pulmonary reactions may occur in neutropenic patients receiving leukocyte transfusions; separation of the infusions as much as possible is advised.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Error prevention: <b>[US Boxed warning]: Verify the product name and dosage if dose exceeds 1.5 mg/kg.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Therapy interruption: If therapy is stopped for &gt;7 days, restart at the lowest dose recommended  and increase gradually.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298744\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134659\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8701&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Stibogluconate: Amphotericin B (Conventional) may enhance the cardiotoxic effect of Sodium Stibogluconate. Specifically, arrhythmia and sudden cardiac death risks may be increased. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134661\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13314057\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women. Refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmis 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13314058\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if amphotericin is excreted into breast milk. Due to its poor oral absorption, systemic exposure to the nursing infant is expected to be decreased; however, because of the potential for toxicity, breast-feeding is not recommended by the manufacturer (Mactal-Haaf 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134663\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BUN and serum creatinine levels should be determined every other day when therapy is increased and at least weekly thereafter. Renal function (monitor frequently during therapy), electrolytes (especially potassium and magnesium), liver function tests, temperature, PT/PTT, CBC; monitor input and output; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134653\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman 1992).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134671\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Poor oral absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Minimal amounts enter the aqueous humor, bile, pericardial fluid, pleural fluid, and synovial fluid</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS penetration:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preterm neonates (GA: 27.4 &plusmn; 5 weeks): High interpatient variability; 40% to 90% of serum concentrations (Baley 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: Poor (inflamed or noninflamed meninges)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">V<sub>d</sub>: Pediatric patients (0 to 18 years): Highly variable; reported range: 0.38 to 3.99 L/kg (Benson 1989; Koren 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates (GA: 27.4 &plusmn; 5 weeks): 14.8 hours (range: 5 to 82 hours) (Baley 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children (4 months to 14 years): 18.1 &plusmn; 6.6 hours (range: 11.9 to 40.3 hours) (Benson 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Biphasic: Initial: 15 to 48 hours; Terminal: 15 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Within 1 hour following a 4- to 6-hour dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (2% to 5% as biologically active form); ~40% eliminated over a 7-day period and may be detected in urine for at least 7 weeks after discontinued use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance (Benson, 1989):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children (8 months to 9 years): 0.57 &plusmn; 0.152 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (10 to 14 years): 0.24 &plusmn; 0.02 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322986\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Amphotericin B Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $45.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134675\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amfucin (PH);</li>\n      <li>Ampho-Moronal (CH);</li>\n      <li>Amphocil (MX);</li>\n      <li>Ampholin (TH);</li>\n      <li>Amphotret (PH, TH);</li>\n      <li>Anfotericina B (DO, GT, PA);</li>\n      <li>Fungilin (QA);</li>\n      <li>Fungilin Lozenges (AU, NZ);</li>\n      <li>Fungitericin (PH);</li>\n      <li>Fungizon (CN, HN);</li>\n      <li>Fungizona (ES);</li>\n      <li>Fungizone (CH, CL, CO, DE, DK, FI, FR, GB, GR, HK, HU, IE, IN, IT, JO, KE, KR, NG, NL, PE, PL, PT, QA, SE, SI, TR, TW, TZ, UY, VE, VN, ZA);</li>\n      <li>Fungso-B (TH);</li>\n      <li>Tericin (BD);</li>\n      <li>Terix (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Arsura EL, Ismail Y, Freedman S, et al, &ldquo;Amphotericin B-Induced Dilated Cardiomyopathy,&rdquo; <i>Am J Med</i>, 1994, 97(6):560-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7985716/pubmed\" target=\"_blank\" id=\"7985716\">7985716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aydin S, Ertugrul B, Gultekin B, Uyar G, Kir E. Treatment of two postoperative endophthalmitis cases due to <i>Aspergillus flavus</i> and <i>Scopulariopsis</i> spp. with local and systemic antifungal therapy. <i>BMC Infect Dis</i>. 2007;7:87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17672897/pubmed\" target=\"_blank\" id=\"17672897\">17672897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baley JE, Meyers C, Kliegman RM, et al, &quot;Pharmacokinetics, Outcome of Treatment, and Toxic Effects of Amphotericin B and 5-Fluorocytosine in Neonates,&quot; <i>J Pediatr</i>, 1990, 116(5):791-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis; Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benson JM and Nahata MC, &ldquo;Clinical Use of Systemic Antifungal Agents,&rdquo; <i>Clin Pharm</i>, 1988, 7(6):424-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3042267/pubmed\" target=\"_blank\" id=\"3042267\">3042267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benson JM and Nahata MC, &ldquo;Pharmacokinetics of Amphotericin B in Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 1989, 33(11):1989-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2610508/pubmed\" target=\"_blank\" id=\"2610508\">2610508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Branch RA, &ldquo;Prevention of Amphotericin B-Induced Renal Impairment. A Review on the Use of Sodium Supplementation,&rdquo; <i>Arch Intern Med</i>, 1988, 148(11):2389-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3056312/pubmed\" target=\"_blank\" id=\"3056312\">3056312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;46(12):1801-1812.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cruz JM, Peacock JE Jr, Loomer L, et al, &ldquo;Rapid Intravenous Infusion of Amphotericin B: A Pilot Study,&rdquo; <i>Am J Med</i>, 1992, 93:123-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1497007/pubmed\" target=\"_blank\" id=\"1497007\">1497007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Devuyst O, Goffin E, and Van Ypersele de Strihou C, &ldquo;Recurrent Hemiparesis Under Amphotericin B for <i>Candida albicans</i> Peritonitis,&rdquo; <i>Nephrol Dial Transplant</i>, 1995, 10(5):699-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7566587/pubmed\" target=\"_blank\" id=\"7566587\">7566587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21498839\"></a>Fisher JF, Sobel JD, Kauffman CA, et al. Candida urinary tract infections &ndash; treatment. <i>Clin Infect Dis</i>. 2011;52(Suppl 6):S457-S466.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/21498839/pubmed\" target=\"_blank\" id=\"21498839\">21498839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gales MA and Gales BJ, &ldquo;Rapid Infusion of Amphotericin B in Dextrose,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(5):523-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7655137/pubmed\" target=\"_blank\" id=\"7655137\">7655137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al; Infectious Diseases Society of America. Coccidioidomycosis. <i>Clin Infect Dis</i>. 2005;41(9):1217-1223. doi: 10.1086/496991.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/16206093/pubmed\" target=\"_blank\" id=\"16206093\">16206093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gallis HA, Drew RH, and Pickard WW, &ldquo;Amphotericin B: 30 Years of Clinical Experience,&rdquo; <i>Rev Infect Dis</i>, 1990, 12(2):308-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2184499/pubmed\" target=\"_blank\" id=\"2184499\">2184499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goodwin SD, Cleary JD, Walawander CA, et al, &ldquo;Pretreatment Regimens for Adverse Events Related to Infusion of Amphotericin B,&rdquo; <i>Clin Infect Dis</i>, 1995, 20(4):755-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7795069/pubmed\" target=\"_blank\" id=\"7795069\">7795069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoenigl M, Krause R. Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis. <i>Curr Pharm Des</i>.2013;19(20):3648-3668.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/23278539/pubmed\" target=\"_blank\" id=\"23278539\">23278539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeffery GM, Beard ME, Ikram RB, et al, &ldquo;Intranasal Amphotericin B Reduces the Frequency of Invasive Aspergillosis in Neutropenic Patients,&rdquo; <i>Am J Med</i>, 1991, 90(6):685-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2042684/pubmed\" target=\"_blank\" id=\"2042684\">2042684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones RS, Barman A, Suh B, et al, &ldquo;Successful Treatment of <i>Aspergillus vertebral</i> Osteomyelitis With Amphotericin B Lipid Complex,&rdquo; <i>Infect Dis Clin Pract</i>, 1995, 4:237-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(10):1255-1265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17968818/pubmed\" target=\"_blank\" id=\"17968818\">17968818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaushik S, Ram J, Brar GS, Jain AK, Chakraborti A, Gupta A. Intracameral amphotericin B: initial experience in severe keratomycosis. <i>Cornea</i>. 2001;20(7):715-719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11588423/pubmed\" target=\"_blank\" id=\"11588423\">11588423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King CT, Rogers PD, Cleary JD, et al, &quot;Antifungal Therapy During Pregnancy,&quot; <i>Clin Infect Dis</i>, 1998, 27(5):1151-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/9827262/pubmed\" target=\"_blank\" id=\"9827262\">9827262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Smith GH, &ldquo;Practical Guidelines for Preparing and Administering Amphotericin B,&rdquo; <i>Am J Hosp Pharm</i>, 1992, 49(5):1156-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1595747/pubmed\" target=\"_blank\" id=\"1595747\">1595747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, Lau A, Klein J, et al, &ldquo;Pharmacokinetics and Adverse Effects of Amphotericin B in Infants and Children,&rdquo; <i>J Pediatr</i>, 1988, 113(3):559-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/3411404/pubmed\" target=\"_blank\" id=\"3411404\">3411404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman CA and Walsh TJ, &ldquo;Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,&rdquo; <i>Drugs</i>, 1992, 44(1):9-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/1379913/pubmed\" target=\"_blank\" id=\"1379913\">1379913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mactal-Haaf C, Hoffman M, and Kuchta A, &quot;Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,&quot; <i>J Hum Lact</i>, 2001, 17(2):160-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11847833/pubmed\" target=\"_blank\" id=\"11847833\">11847833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohr J, Johnson M, Cooper T, et al, &ldquo;Current Options in Antifungal Pharmacotherapy,&rdquo; <i>Pharmacotherapy</i>, 2008, 28(5):614-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/18447660/pubmed\" target=\"_blank\" id=\"18447660\">18447660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nesbit SA, Ketz KE, McClain BW, et al. Comparison of two concentrations of amphotericin B bladder irrigation in the treatment of funguria in patients with indwelling urinary catheters. <i>Am J Health Syst Pharm</i>. 1999;56(9):872- 875.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10344610/pubmed\" target=\"_blank\" id=\"10344610\">10344610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span><span class=\"doi\">10.1093/cid/civ933</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel R, &ldquo;Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,&rdquo; <i>Mayo Clin Proc</i>, 1998, 73(12):1205-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/9868423/pubmed\" target=\"_blank\" id=\"9868423\">9868423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html. Accessed August 8, 2016.27365388</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &ldquo;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pilmis B, Jullien V, Sobel J, et al. Antifungal drugs during pregnancy: an updated review. <i>J Antimicrob Chemother</i>. 2015;70(1):14-22. doi: 10.1093/jac/dku355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/25204341/pubmed\" target=\"_blank\" id=\"25204341\">25204341</a>]</span><span class=\"doi\">10.1093/jac/dku355</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rex JH, Bennett JE, Sugar AM, &ldquo;A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,&rdquo; <i>N Engl J Med</i>, 1994, 331(20):1325-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/7935701/pubmed\" target=\"_blank\" id=\"7935701\">7935701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. <i>Clin Infect Dis</i>. 2011;52(5):648-653. doi: 10.1093/cid/ciq204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/21239843/pubmed\" target=\"_blank\" id=\"21239843\">21239843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ritterband D, Kelly J, McNamara T, Kresloff M, Koplin R, Seedor J. Delayed-onset multifocal polymicrobial keratitis after laser in situ keratomileusis. <i>J Cataract Refract Surg</i>. 2002;28(5):898-899.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11978476/pubmed\" target=\"_blank\" id=\"11978476\">11978476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slain D, &ldquo;Lipid-Based Amphotericin B for the Treatment of Fungal Infections,&rdquo; <i>Pharmacotherapy</i>, 1999, 19(3):306-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/10221369/pubmed\" target=\"_blank\" id=\"10221369\">10221369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DA and Shatsky SA, &quot;Intrathecal Amphotericin in the Management of Coccidioidal Meningitis,&quot; <i>Semin Respir Infect</i>, 2001, 16(4):263-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/11740828/pubmed\" target=\"_blank\" id=\"11740828\">11740828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tamcelik N, Ozdamar A, Kizilkaya M, Devranoglu K, Ustundag C, Demirkesen C. Fungal keratitis after nonpenetrating glaucoma surgery. <i>Cornea</i>. 2002;21(5):532-534.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/12072733/pubmed\" target=\"_blank\" id=\"12072733\">12072733</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    The Ad Hoc Advisory Panel on Peritonitis Management. &ldquo;Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis Treatment Recommendations: 1989 Update,&rdquo; <i>Perit Dial Int</i>, 1989, 9(4):247-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/2488376/pubmed\" target=\"_blank\" id=\"2488376\">2488376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>. Accessed September 29, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed September 29, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(7):807-825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-deoxycholate-conventional-drug-information/abstract-text/17806045/pubmed\" target=\"_blank\" id=\"17806045\">17806045</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8701 Version 139.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7254335\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134687\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F134709\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F134690\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F134703\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F134691\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F134692\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22902758\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134665\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F134650\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F747024\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F134669\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475062\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134718\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134657\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134672\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134654\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298744\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134659\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134661\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13314057\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13314058\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F134663\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134653\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F134671\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322986\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F134675\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8701|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-patient-drug-information\" class=\"drug drug_patient\">Amphotericin B deoxycholate (conventional): Patient drug information</a></li><li><a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">Amphotericin B deoxycholate (conventional): Pediatric drug information</a></li></ul></div></div>","javascript":null}